Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06459973
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-05-30
Brief Title:
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
Sponsor:
MediLink Therapeutics Suzhou Co Ltd
Organization:
MediLink Therapeutics Suzhou Co Ltd
Study Overview
Official Title:
A Multi-center Open-label Phase III Clinical Study to Evaluate the Safety Tolerability Pharmacokinetic Characteristics and Preliminary Efficacy of YL205 in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multicenter open-label phase III study of YL205 in China to evaluate the safety tolerability PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None